Boston Scientific Corp (BSX) observes a 4% drop in stock following the FARAPULSE study update.
Q3 earnings exhibit revenue and EPS beat, supporting an increase in the annual forecast due to a strong demand for its heart devices. However, despite satisfactory Q3 results, the company's stock falls in premarket due to reduced operating margins. BSX still anticipates the Axonics agreement to close this year.
Dakota Wealth Management purchases 7,455 of BSX's shares. BSX surpasses Q3 earnings and revenue estimates, making it an attractive investment. This profit growth reflects positively on BSX compared to other medical stocks lagging this year. BSX receives a price target increase to $100 from $90 at BofA amidst all the market activities. BSX's innovation can be seen with the launch of its
Ablation System, causing a surge in the company's growth. However, the strong performance might be overshadowed by the slowing rates of return at Boston Scientific. The closing of its acquisition of
Silk Road Medical, Inc. offers another significant milestone for the corporation. Despite this, BSX's stock shows a decline when compared with a broader market.
Boston Scientific Corp BSX News Analytics from Tue, 27 Feb 2024 08:00:00 GMT to Sat, 26 Oct 2024 19:06:04 GMT -